Varian passes on an acquisition option as Augmenix closes a Series D funding round with $10.8 million raised in support of its Space OAR hydrogel for protecting the rectum during prostate radiation therapy.
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
Elekta hopes to meet Turkey's radiotherapy "shortage" through its acquisition of local distributor Mesi Medikal.
California medtech maker Accuray boosts its full-year revenue outlook after posting Q3 2014 sales nearly 40% higher than last year.
Radiosurgery systems maker Accuray (NSDQ:ARAY) sees continued momentum on the horizon as a boost in Q3 sales prompts an updated, increased full-year outlook.
California-based Varian Medical System shaves 16¢ off of its per-share earnings for charges related to a patent infringement settlement with the University of Pittsburgh.
Radiosurgery devices maker Varian Medical (NYSE:VAR) posted a tough quarter, with sales up a modest 1.3% and earnings sucked up by legal charges in its 2nd quarter.
Varian Medical Systems agrees to pay about $35 million to settle a patent infringement lawsuit brought by the University of Pittsburgh, after a federal appeals court overturns a portion of its $100 million loss to Pitt.
Varian Medical (NYSE:VAR) said it settled its patent infringement beef with the University of Pittsburgh for $35 million, after a federal appeals court overturned a portion of the $100 million award Pitt won in 2012.
RefleXion Medical secures an $11.6 million Series A funding round in support of its cancer-targeting bio-guided radiation therapy system.
California-based medtech group RefleXion Medical touted an $11.6 million Series A fundraising round, hoping to use the new funds to expand research & development efforts for its guided radiation therapy technology.
Halt Medical has big plans for its Acessa System for treating uterine fibroids, having raised nearly $93 million in efforts to restructure debt and fund its commercial efforts.
California women's health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.